Apoptotic Properties of Rutheinum Complexes on Different Type of Cancer Cell Lines †
Abstract
:1. Introduction
2. Materials and Methods
3. Results
4. Discussion
Acknowledgments
References
- Allardayce, C.S.; Dyson, P.J. Ruthenium in medicine: Current clinical uses and future prospect. Platinum Met. Rev. 2001, 45, 62–69. [Google Scholar]
- Guisado-Barrios, G.; Hiller, J.; Peris, E. Pyracene-Linked Bis-Imidazolylidine Complexes of Palladium and Some Catalytic Benefits Produced by Bimetallic Catalyst. Chem. Eur. J. 2013, 19, 10405–10411. [Google Scholar] [CrossRef] [PubMed]
- Ang, W.H.; Dyson, P.J. Classical and Non-Classical Ruthenium-Based Anticancer Drugs: Towards Targeted Chemotherap. Eur. J. Inorg. Chem. 2006, 20, 4003–4018. [Google Scholar] [CrossRef]
- Hotze, A.C.G.; Caspers, S.E.; de Vos, D.; Kooijman, H.; Spek, A.L.; Flamigni, A.; Bacac, M.; Sava, G.; Haasnoot, J.G.; Reedijk, J. Structure-dependent in vitro cytotoxicity of the isomeric complexes [Ru(L)2Cl2] (L=o-tolylazopyridine and 4-methyl-2-phenylazopyridine) in comparison to [Ru(azpy)2Cl2]. JBIC J. Biol. Inorg. Chem. 2004, 9, 354–364. [Google Scholar] [CrossRef] [PubMed]
- Mendoza-Ferri, M.-G.; Hartinger, C.G.; Nazarov, A.A.; Kandioller, W.; Severin, K.; Keppler, B.K. Modifying the structure of dinuclear ruthenium complexes with antitumor activity. Appl. Organomet. Chem. 2008, 22, 326–332. [Google Scholar] [CrossRef]
- Novakova, O.; Kasparkova, J.; Vrana, O.; Vanvliet, P.M.; Reedijk, J.; Brabec, V. Correlation between Cytotoxicity and DNA-Binding of Polypyridyl Ruthenium Complexe. Biochemistry 1995, 34, 12369–12378. [Google Scholar] [CrossRef] [PubMed]
- Ohndorf, U.M.; Rould, M.A.; He, Q.; Pabo, C.O.; Lippard, S.J. Basis for Recognition of cisplatin-modified DNA by high-mobility-group proteins. Nature 1999, 399, 708–712. [Google Scholar] [CrossRef] [PubMed]
- Wong, E.; Giandomenico, C.M. Current status of platinum-based antitumor drug. Chem. Rev. 1999, 99, 2451–2465. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Vatansever, H.S.; Kabadayı, H.; Korkmaz, M.; Özdal-Kurt, F.; Kavukcu, S.B.; Türkmen, H. Apoptotic Properties of Rutheinum Complexes on Different Type of Cancer Cell Lines. Proceedings 2018, 2, 1593. https://doi.org/10.3390/proceedings2251593
Vatansever HS, Kabadayı H, Korkmaz M, Özdal-Kurt F, Kavukcu SB, Türkmen H. Apoptotic Properties of Rutheinum Complexes on Different Type of Cancer Cell Lines. Proceedings. 2018; 2(25):1593. https://doi.org/10.3390/proceedings2251593
Chicago/Turabian StyleVatansever, Hafize Seda, Hilal Kabadayı, Mehmet Korkmaz, Feyzan Özdal-Kurt, Serdar Batıkan Kavukcu, and Hayati Türkmen. 2018. "Apoptotic Properties of Rutheinum Complexes on Different Type of Cancer Cell Lines" Proceedings 2, no. 25: 1593. https://doi.org/10.3390/proceedings2251593
APA StyleVatansever, H. S., Kabadayı, H., Korkmaz, M., Özdal-Kurt, F., Kavukcu, S. B., & Türkmen, H. (2018). Apoptotic Properties of Rutheinum Complexes on Different Type of Cancer Cell Lines. Proceedings, 2(25), 1593. https://doi.org/10.3390/proceedings2251593